NSAIDs downgraded in new guidelines for juvenile arthritis

Initial NSAID monotherapy for polyarthritis in juvenile idiopathic arthritis (JIA) has been rejected in the most recent 2019 American College of Rheumatology / Arthritis Foundation guidelines. The guidelines differ from the earlier 2011 version in recognising ‘the established benefits of early initiation of DMARD treatment’. As a result, NSAIDs have been downgraded to adjunct therapy, ...

Already a member?

Login to keep reading.

© 2021 the limbic